Legacy drugs accounted for half of pharmaceutical sales at Roche in 2017, but this was partially offset by strong growth for a group of recently launched products including new medicines for multiple sclerosis, haemophilia A and cancer. ---Subscribe to MedNous to access this article--- Company News
